Company intelligence / Profile preview

Omnio

Umeå, Sweden

Ownership: Private
Development stage: Commercial

Overview

Omnio is developing a recombinant plasminogen therapy to treat chronic wounds, with a primary focus on diabetic foot ulcers. Preclinical data suggest that their approach can restart stalled healing processes in chronic wounds by leveraging the biological role of plasminogen in tissue repair and inflammation resolution. The company is preparing for phase IIa/b clinical trials in 2026–2027

Therapeutic areas: EndocrinologyDermatology
Modalities: Recombinant proteinBiologic (specifically recombinant plasminogen)
Industry: Biotech

Partnerships

Omnio collaborates with academic partners including Umeå University; seeking additional strategic partnerships as it scales up development and manufacturing

Beyond the preview

Go deeper on Omnio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omnio.

Explore the full profile